Disease Oriented Biobanks is the fastest growing segment, North America is the largest regional market
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Key Market Drivers
The increased demand for high-quality biospecimens in research represents a primary market driver, stemming from the critical need for reliable biological materials in scientific inquiry. The integrity and standardized processing of samples are crucial for producing reproducible research outcomes across diverse disciplines including oncology, neuroscience, and infectious diseases.This stringent demand compels biobanks to implement rigorous quality control measures and advanced storage protocols. According to a July 2024 arXiv article, "Quantifying the Impact of Biobanks and Cohort Studies", 2,663 unique biobanks were mentioned across 228,761 scientific articles as of October 2023, underscoring their critical role in research dissemination and impact. This extensive utilization demonstrates the sustained reliance of the scientific community on robust biospecimen repositories to advance medical understanding.
Key Market Challenges
The substantial upfront capital expenditure required for establishing and maintaining modern biobanking facilities presents a significant challenging factor. This financial barrier directly impedes the expansion of the global biobanks market by limiting the entry of new organizations and restricting the growth capabilities of smaller existing entities. Establishing a biobank necessitates considerable investment in specialized infrastructure, advanced equipment for sample processing and long-term storage, and ongoing expenditure for stringent regulatory compliance and highly skilled personnel. The cumulative financial commitment for such operations is substantial.Key Market Trends
The Global Biobanks Market is significantly shaped by the increasing prevalence of cord blood and stem cell banking. This trend is driven by growing awareness of stem cells' therapeutic potential across various medical conditions, including hematological disorders and certain cancers. The World Marrow Donor Association (WMDA) reported a substantial inventory of 760,832 cord blood units as of July 2024, demonstrating the scale of these specialized biobanking efforts. This growth is further supported by an expanding number of medical applications and ongoing research into regenerative medicine.Key Market Players Profiled:
- Danaher Corporation
- Merck KgaA
- Becton, Dickinson, and Company
- Avantor, Inc.
- Thermo Fisher Scientific, Inc
- Tecan Trading AG
- QIAGEN N.V.
- Hamilton Company
- ProMedDx, LLC
- ISENET Biobanking S.r.l
Report Scope:
In this report, the Global Biobanks Market has been segmented into the following categories:By Type:
- Disease Oriented Biobanks
- Population Based Biobanks
- Tissue Biobanks
- Others
By Sample Type:
- Blood Products
- Biological Fluids
- Nucleic Acid
- Cell Lines
- Others
By Application:
- Therapeutics
- Drug Discovery
- Clinical Diagnostics
- Clinical Research
By End User:
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospitals & Clinics
- Others
By Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Biobanks Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
The companies profiled in this Biobanks market report include:- Danaher Corporation
- Merck KgaA
- Becton, Dickinson, and Company
- Avantor, Inc.
- Thermo Fisher Scientific, Inc
- Tecan Trading AG
- QIAGEN N.V.
- Hamilton Company
- ProMedDx, LLC
- ISENET Biobanking S.r.l
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 184 |
| Published | November 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 79.34 Billion |
| Forecasted Market Value ( USD | $ 132.91 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |


